Summary
Definição
História e exame físico
Principais fatores diagnósticos
- calf swelling
- pain or tenderness along deep venous system
- chest pain
- tachypnea
- breathlessness
- hypotension
- tachycardia
Outros fatores diagnósticos
- family history of venous thromboembolism (VTE)
Fatores de risco
- history of unprovoked venous thromboembolism
- increasing age
- pregnancy/postpartum
- obesity
- smoking
- malignancy
- acute inflammatory state
- antiphospholipid antibodies (aPLs)
- myeloproliferative disorders
- nephrotic syndrome
- Behcet disease
- HIV infection
- disseminated intravascular coagulation
- paroxysmal nocturnal hemoglobinuria
- heparin-induced thrombocytopenia
- estrogen-containing oral birth control pill/hormone replacement therapy/selective estrogen receptor modulator therapy
- chemotherapy
- surgery
- long-haul flight (>4 hours)
- antithrombin deficiency
- protein C deficiency
- protein S deficiency
- plasminogen deficiency
- elevated fibrinogen
- dysfibrinogenemia
- factor V Leiden
- prothrombin gene mutation (G-20210-A; also referred to as F2 c.*97G>A variant)
- elevated factor VIII levels (>150 U/L)
- elevated levels of factor IX or XI
- hyperhomocysteinemia
- sickle cell disease
- elevated levels of thrombin-activatable fibrinolysis inhibitor (TAFI)
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- CBC
- peripheral blood smear
- activated partial thromboplastin time (aPTT)
- fibrinogen
- prothrombin time (PT)
- D-dimer
- serum albumin
- serum creatinine
- serum cholesterol
- serum triglycerides
Tests to avoid
- homocysteine level
Investigações a serem consideradas
- heritable thrombophilia test
- polymerase chain reaction (PCR) for factor V Leiden
- antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, anti-beta-2 glycoprotein 1 antibodies)
- factor VIII level
- myeloproliferative neoplasm panel
- flow cytometry for paroxysmal nocturnal hemoglobinuria
- heparin-induced thrombocytopenia (HIT) test
- chest x-ray
- abdominal CT
- abdominal ultrasound
- tumor markers
- 24-hour urine collection for protein, or spot urine for protein/creatinine ratio
Treatment algorithm
nonpregnant: no cancer and with an acute medical illness
nonpregnant: with cancer
nonpregnant: undergoing nonorthopedic surgery
nonpregnant: undergoing orthopedic surgery
nonpregnant with major trauma
pregnant
Contributors
Authors
Lara N. Roberts, MBBS, MD (Res), FRCP, FRCPath
Consultant Haematologist
King's Thrombosis Centre
King's College Hospital
London
UK
Disclosures
LNR has received speaker fees from Bayer and Viatris.
Roopen Arya, BMBCh (Oxon), MA, PhD, FRCP, FRCPath
Professor of Thrombosis and Haemostasis
King's Thrombosis Centre
King's College NHS Foundation Trust
London
UK
Disclosures
RA declares that he has no competing interests.
Peer reviewers
Beverly Hunt, FRCP, FRCPath, MD
Professor of Thrombosis & Haemostasis
King's College
Consultant
Departments of Haematology, Pathology & Rheumatology
Lead in Blood Sciences
Guy's & St Thomas' NHS Foundation Trust
London
UK
利益声明
BH declares that she has no competing interests.
Per Morten Sandset, MD, PhD
Senior Consultant and Head of Department
Oslo University Hospital Ullevål
Department of Hematology
Professor in Hematology
University of Oslo
Oslo
Norway
利益声明
PMS declares that he has no competing interests.
Michael Bromberg, MD, PhD
Associate Professor
Director of Hematologic Malignancies
Medicine and Pharmacology
Temple University School of Medicine
Philadelphia
PA
Declarações
MB declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referências
Principais artigos
Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S-736S.Texto completo Resumo
American College of Chest Physicians. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. CHEST. 2012;141(suppl 2):e1-801.Texto completo
Arachchillage DJ, Mackillop L, Chandratheva A, et al. Thrombophilia testing: A British Society for Haematology guideline. Br J Haematol. 2022 Aug;198(3):443-58.Texto completo Resumo
Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944.Texto completo Resumo
Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023 Jun 1;41(16):3063-71.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication].Texto completo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diretrizes
- NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease
- Venous thromboembolism in cancer patients: clinical practice guideline
Mais DiretrizesFolhetos informativos para os pacientes
Deep vein thrombosis
Sickle cell disease
Mais Folhetos informativos para os pacientes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal